US FDA’s Sunscreen Proposal Rattles International Trade, And What About Public Health?
Executive Summary
European and Japanese trade groups are concerned that the US FDA could be orchestrating global trade disruptions, and possible health crises, with its proposed order to amend the OTC sunscreen monograph in a way that would stymie use of commonly used UV filters with demonstrably safe market histories.
You may also be interested in...
PCPC, CHPA Ask US FDA To Defer Final Rulemaking On Sunscreen Actives In GRASE Limbo
Industry continues working to support updated GRASE findings for UV filters avobenzone, homosalate, octinoxate, octisalate, octocrylene, oxybenzone, ensulizole and meradimate, which the FDA categorized more than two years ago as lacking data, a position it reprised in 2021 under its overhauled OTC monograph system.
CIR Defends Preservative Stance As NGO Says Restrictions On MI, MCI/MI Are ‘Not Working’
Asked to reconsider its assessments of methylisothiazolinone and the methylchloroisothiazolinone/MI combination, CIR takes a stand against further depletion of the cosmetic industry’s preservative palette in favor of risk-mitigating tools and strategies employed by product formulators. A preview of the CIR Expert Panel's 6-7 December meeting.
FDA’s Proposed Order For Sunscreens, A First Under OTC Reforms, Reprises 2019 Proposed Rule
As anticipated, the US FDA’s proposed order for sunscreens released on 24 September creates a bridge to the agency’s 2019 proposed rule before the CARES Act overhauled OTC drug review in March 2020.